-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
National Pharmaceutical Economic Information Conference Kicks Off | Shijiazhuang Sihua Pharmaceutical Group Honored as a “Leading Force” in China’s High-Quality Pharmaceutical Development for 2022
Category:
发布时间：2023-02-21
【概要描述】
In early spring, Zhuhai in Guangdong Province, located in the Guangdong–Hong Kong–Macao Greater Bay Area, is awash with blossoms and brimming with vitality. On the evening of February 19, the “2022 Comprehensive Review of High-Quality Pharmaceutical Development: Identifying Leading Forces in Multipolar Growth Tracks” award ceremony—the 34th installment of the National Pharmaceutical Economic Information Release Series hosted by the Southern Institute of Pharmaceutical Economics under the National Medical Products Administration and organized by the Pharmaceutical Economic Daily—was solemnly announced. Shijiazhuang Sihua Pharmaceutical Group was honored as a “Leading Force in China’s High-Quality Pharmaceutical Development for 2022”—specifically recognized as an Outstanding Enterprise for High-Quality Development and an Outstanding Brand (for its Yibedi-brand cefdinir capsules).
In early spring, Zhuhai in Guangdong Province, located in the Guangdong–Hong Kong–Macao Greater Bay Area, is awash with blossoms and brimming with vitality. On the evening of February 19, the “2022 Comprehensive Review of High-Quality Pharmaceutical Development: Identifying Leading Forces in Multipolar Growth Tracks” selection—part of the 34th National Pharmaceutical Economic Information Release Series hosted by the Southern Institute of Pharmaceutical Economics under the National Medical Products Administration and organized by the Pharmaceutical Economic Daily—was solemnly announced. Shijiazhuang Sihua Pharmaceutical Group was honored as a 2022 Leading Force in China’s High-Quality Pharmaceutical Development, receiving both the Corporate Achievement Award for Outstanding Performance and the Brand Achievement Award for the Yibedi brand cefdinir capsules.
Focusing on the present, the post-pandemic global transformation is ushering in a new stable state for China’s pharmaceutical economy: overall scale is growing steadily, profit drivers are diversifying and being restructured, the regulatory framework is gradually improving, supervisory capacity has been significantly strengthened, standards are being upgraded to align with international norms, cutting-edge innovation is increasingly interconnected on a global scale, formulary adjustments are being advanced in stages, volume-based procurement has become routine, competitive order is continuously being standardized, competition and collaboration at the end-user level are intensifying, and the dividend from essential medication needs is promising. This is a new era of upholding fundamental principles while embracing innovation and forging ahead with courage and determination—a new starting point for uniting hearts and minds and riding the winds of change to move forward together. The Southern Institute of the National Medical Products Administration is focusing on the leading forces driving industry development, committed to showcasing the resilience and vitality of the pharmaceutical sector, illuminating the path of relentless progress, unlocking the potential for industrial upgrading, and striving to establish benchmark standards that set the pace for the industry.
In 2022, guided by the Healthy China initiative, the pharmaceutical industry leveraged innovation to drive development, strategically positioning itself at the forefront of the sector and continuously attracting and concentrating innovative resources. As a result, a cohort of industry-leading enterprises has emerged as new pioneers, practitioners, and leaders in China’s pharmaceutical sector. Shijiazhuang Sihua Pharmaceutical Group stands out as an exemplary representative: it aligns its innovation chain with the industrial value chain, maintains a leading position in the industry in terms of the number of approved and filed generic drug R&D projects, and consistently uses innovation as a key driver to propel the company toward the mid- to high-end segments of the industry, thereby becoming a major force in the development of top-tier industry players.
According to reports, the 2022 China Pharmaceutical Industry High-Quality Development “Leading Forces” selection was conducted across multiple dimensions—including international recognition, operational stability index, performance metrics, and social responsibility index—through a rigorous, multi-stage evaluation process, with the aim of recognizing the industry’s key players who remain true to their original mission and continue to pioneer new frontiers.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091